Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Minskning av återcirkulation av blod i veno-venös ECMO

13 november 2026 uppdaterad av: Steffen Weber-Carstens, Charite University, Berlin, Germany

Minskning av blodåtercirkulation i veno-venös ECMO genom ultraljudsutspädningsmätningar (ECMO Circulation Study)

Blood which recirculates through the circuit of a veno-venous Extracorporeal Membrane Oxygenation (V-V ECMO) does not contribute to the systemic oxygenation of a patient on V-V ECMO and is called the recirculation fraction (Rf). Theoretically, the optimization of ECMO blood flow is possible using Rf measurements.

A prospective, observational study will be performed measuring the Rf of total ECMO blood flow in patients with acute respiratory distress syndrome (ARDS) on V-V ECMO with an ultrasound dilution technique.

ECMO blood flow will be optimized by reducing ECMO blood flow in accordance with the measured Rf as long as systemic oxygenation is not compromised.

Studieöversikt

Detaljerad beskrivning

Based on data from the 'Blood Recirculation and vvECMO' trial (ClinicalTrials.gov ID: NCT03200314) (i.e. an expected frequency of successful blood flow reduction of 66.7%), using a one-sample Chi square test, a two-sided type-1 error of 5%, a power of 80%, a total of 68 patients is needed to show that the proportion of patients with a secure ECMO blood flow reduction is greater than 50%. Presumably, 136 Patients have to be included into the trial to study 68 patients with a relevant Rf since not all patients on V-V ECMO suffer from a high Rf.

Studietyp

Observationell

Inskrivning (Faktisk)

77

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • State of Berlin
      • Berlin, State of Berlin, Tyskland, 13353
        • Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Sannolikhetsprov

Studera befolkning

Inclusion Criteria:

  • patients aged 18 years or older
  • ARDS
  • veno-venous ECMO

Exclusion Criteria:

  • age < 18 years
  • hemodynamic instability during measurement of recirculation
  • pregnancy
  • inability to obtain patient's consent or consent of legal guardian

Beskrivning

Patients aged 18 years or older requiring veno-venous ECMO for treatment of refractory hypoxemia in ARDS.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Successful ECMO blood flow reduction
Tidsram: Once within the first week after initiation of ECMO therapy

Number of patients with a relevant recirculation fraction and successful ECMO blood flow reduction

Once within the first week after initiation of ECMO therapy

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Recirculation fraction
Tidsram: Once within the first week after initiation of ECMO therapy

Fraction of blood recirculating through the ECMO circuit

Once within the first week after initiation of ECMO therapy
Arterial blood oxygen content
Tidsram: Once within the first week after initiation of ECMO therapy

Arterial blood oxygen content before vs. after reduction of ECMO blood flow

Once within the first week after initiation of ECMO therapy
Extracorporeal blood Flow
Tidsram: Once within the first week after initiation of ECMO therapy

ECMO Blood Flow before vs. after reduction of ECMO blood flow

Once within the first week after initiation of ECMO therapy
Extracorporeal gas flow
Tidsram: Once within the first week after initiation of ECMO therapy

ECMO Sweep Gas flow

Once within the first week after initiation of ECMO therapy
Length of ECMO therapy
Tidsram: Daily until the end of ECMO therapy (approximately 14 days)

Days on ECMO

Daily until the end of ECMO therapy (approximately 14 days)
Cannula position and distance
Tidsram: Once within the first week after initiation of ECMO therapy

The distance between the tip of drainage and return cannula will be measured in the existing medical imaging (e.g. CT scans)

Once within the first week after initiation of ECMO therapy
Right heart dysfunction
Tidsram: Once within the first week after initiation of ECMO therapy

Existing echocardiography will be evaluated for possible right heart dysfunction

Once within the first week after initiation of ECMO therapy
Length of mechanical ventilation
Tidsram: Entire duration of the ICU stay (approximately 28 days)

Length of mechanical ventilation

Entire duration of the ICU stay (approximately 28 days)
Complications of ECMO therapy
Tidsram: Length of ECMO therapy (approximately 14 days)

Incidence of cannula or system changes (i.e. due to circuit clotting), complications attributed to ECMO therapy like bleeding complications from the cannulation site, transfusion requirements, hemolysis

Length of ECMO therapy (approximately 14 days)
ICU mortality
Tidsram: Entire duration of the ICU stay (approximately 28 days)

ICU mortality

Entire duration of the ICU stay (approximately 28 days)
ICU length of stay
Tidsram: Entire duration of the ICU stay (approximately 28 days)

ICU length of stay

Entire duration of the ICU stay (approximately 28 days)
Incidence of ICU-acquired organ dysfunctions and complications
Tidsram: Entire duration of the ICU stay (approximately 28 days)

Cerebral-, cardiovascular-, cardiac- pulmonary-, gastrointestinal- and renal dysfunctions, ICU-acquired infections

Entire duration of the ICU stay (approximately 28 days)
ECMO blood flow over time
Tidsram: Daily until the end of ECMO therapy (approximately 14 days)

ECMO blood and sweep gas flow over time

Daily until the end of ECMO therapy (approximately 14 days)
ECMO sweep gas flow over time
Tidsram: Daily until the end of ECMO therapy (approximately 14 days)

ECMO sweep gas flow over time

Daily until the end of ECMO therapy (approximately 14 days)
Mobility at ICU discharge
Tidsram: Discharge from the ICU (approximately 28 days)

Level of mobility the patient has reached at ICU discharge (recumbent, sitting, standing, walking with help, walking independently)

Discharge from the ICU (approximately 28 days)
Weaning level at ICU discharge
Tidsram: Discharge from the ICU (approximately 28 days)

Level of weaning reached at ICU discharge

Discharge from the ICU (approximately 28 days)
Status of mechanical ventilation at ICU discharge
Tidsram: Discharge from the ICU (approximately 28 days)

Status of mechanical ventilation at ICU discharge including all relevant settings and parameters

Discharge from the ICU (approximately 28 days)
Level of organ dysfunction at ICU discharge
Tidsram: Discharge from the ICU (approximately 28 days)

Sepsis-related Organ Failure Assessment Score at ICU discharge

Discharge from the ICU (approximately 28 days)
Level of consciousness at ICU discharge
Tidsram: Discharge from the ICU (approximately 28 days)

Glasgow Coma Scale at ICU discharge

Discharge from the ICU (approximately 28 days)
Level of disease severity
Tidsram: Discharge from the ICU (approximately 28 days)

Acute Physiology And Chronic Health Evaluation at ICU discharge

Discharge from the ICU (approximately 28 days)
Hospital acquired infections related to ECMO therapy
Tidsram: Entire duration of ECMO therapy

Infection/colonisation of the ECMO circuit

Entire duration of ECMO therapy
Bleeding and thrombembolic complications of ECMO therapy
Tidsram: Entire duration of ECMO therapy

Bleeding complications, thrombembolic events, overall use of blood products and coagulation factors, electron microscopic evaluation of selected membranes after change or weaning of the ECMO circuit

Entire duration of ECMO therapy

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Martin Russ, Dr. med., Charite University Hospital Berlin
  • Huvudutredare: Philipp A Pickerodt, Dr. med., Charite University Hospital Berlin
  • Huvudutredare: Vladimir Skrypnikov, Dr. med., Charite University Hospital Berlin
  • Huvudutredare: Steffen Weber-Carstens, Prof. Dr. med., Charite University Hospital Berlin

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

20 november 2020

Primärt slutförande (Faktisk)

5 maj 2026

Avslutad studie (Faktisk)

5 maj 2026

Studieregistreringsdatum

Först inskickad

14 september 2020

Först inskickad som uppfyllde QC-kriterierna

12 februari 2021

Första postat (Faktisk)

15 februari 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

13 november 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • EA115620

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera